Efficacy and Safety of Bosentan Treatment for Portopulmonary Hypertension Associated With Syncope
-
- Sato Akinori
- Department of Cardiology, Niigata Prefectural Shibata Hospital Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
-
- Maie Kouichiro
- Department of Cardiology, Niigata Prefectural Shibata Hospital
-
- Ohno Yukako
- Department of Cardiology, Niigata Prefectural Shibata Hospital Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
-
- Yoshida Tsuyoshi
- Department of Cardiology, Niigata Prefectural Shibata Hospital
-
- Ito Eiichi
- Department of Cardiology, Niigata Prefectural Shibata Hospital
-
- Tanabe Yasuhiko
- Department of Cardiology, Niigata Prefectural Shibata Hospital
-
- Aizawa Yoshifusa
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
この論文をさがす
抄録
Pulmonary arterial hypertension (PAH) in patients with portal hypertension is also referred to as portopulmonary hypertension (PPHTN). Here, we report a case of PPHTN caused by alcoholic liver cirrhosis in a 43-year-old male who experienced repetitive syncope on exertion. The continuous monitoring of pulmonary artery pressure and radial artery pressure revealed that his PAH was aggravated with a drop in systemic arterial pressure during an exercise test. Bosentan, an endothelin A/B receptor antagonist, improved the patient’s hemodynamic parameters and abolished his syncope without adverse effects. This is the first report that bosentan may be effective and safe for PPHTN associated with syncope.
収録刊行物
-
- International Heart Journal
-
International Heart Journal 52 (4), 243-245, 2011
一般社団法人 インターナショナル・ハート・ジャーナル刊行会